Wang J L, Liu H J, Li F, Yang W Y, Wang J M, Tan S F, Wang Q
Department of Clinical Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Urology Linyi People's Hospital of Shandong Province, Linyi, China.
Genet Mol Res. 2015 Nov 24;14(4):14967-78. doi: 10.4238/2015.November.24.4.
Our study aimed to investigate the association between multidrug resistance (MDR1) gene polymorphisms and the response to imatinib (IM) in chronic myeloid leukemia (CML). An electronic databases in PubMed, Cochrane Library, Wanfang, China National Knowledge Infrastructure, and VIP were searched using combinations of keywords relating to MDR1 polymorphisms and the response to IM in CML. Studies retrieved from database searches were screened using stringent inclusion and exclusion criteria. The Comprehensive Meta-analysis 2.0 software was utilized for all statistical analyses. In total, 186 studies were initially retrieved, and 10 studies, involving 987 CML patients, were eventually included in this meta-analysis. Results of our study revealed no significant associations between MDR1 rs1045642, rs1128503, and rs2032582 polymorphisms and major molecular response and complete molecular response in CML patients. Significant differences were observed in the genotype frequencies of MDR1 rs1128503 under homozygous, heterozygous, and recessive models, between CML patients sensitive and resistant to IM. A significant difference in genotype frequencies of MDR1 rs2032582 was also observed under allele, homozygous, heterozygous, and recessive models between CML patients sensitive and resistant to IM. In conclusion, based on our meta-analysis, the MDR1 polymorphisms, rs1045642, rs1128503, and rs2032582, are not directly correlated with the curative effect of IM treatment of CML patients.
我们的研究旨在探讨多药耐药（MDR1）基因多态性与慢性髓性白血病（CML）患者对伊马替尼（IM）反应之间的关联。通过组合与MDR1多态性及CML患者对IM反应相关的关键词，检索了PubMed、Cochrane图书馆、万方、中国知网和维普等电子数据库。使用严格的纳入和排除标准对从数据库检索中获得的研究进行筛选。所有统计分析均采用Comprehensive Meta-analysis 2.0软件。总共初步检索到186项研究，最终有10项研究（涉及987例CML患者）纳入本荟萃分析。我们的研究结果显示，MDR1 rs1045642、rs1128503和rs2032582多态性与CML患者的主要分子反应和完全分子反应之间无显著关联。在对IM敏感和耐药的CML患者之间，MDR1 rs1128503在纯合子、杂合子和隐性模型下的基因型频率存在显著差异。在对IM敏感和耐药的CML患者之间，MDR1 rs2032582在等位基因、纯合子、杂合子和隐性模型下的基因型频率也存在显著差异。总之，基于我们的荟萃分析，MDR1多态性rs1045642、rs1128503和rs2032582与IM治疗CML患者的疗效无直接相关性。
